Breast cancer mortality after eight years of an improved screening program using digital breast tomosynthesis

Abstract

Objectives To assess screening quality metrics and to describe mortality rates eight years after redesign of breast cancer screening and diagnosis pathways, and the introduction of digital breast tomosynthesis. Setting Breast Unit of the Toledo Health Area in the region of Castilla-La Mancha (Spain). Methods We recorded screening metrics and mortality data following the introduction of digital breast tomosynthesis in 2011 for screening and diagnosis pathways. We then compared the mortality between Toledo Health Area and the rest of Castilla-La Mancha, where digital breast tomosynthesis is not available. Results All screening quality metrics improved following the introduction of digital breast tomosynthesis. The cancer detection rate significantly increased from 2.3 (95% confidence interval (CI): 1.9–3.6) to 4.5 per 1000 women (95% CI: 3.2–5.2) on average between the periods 2005–2009 and 2015–2018, while the recall rate significantly decreased from 7.0% (95% CI: 6.8%–8.2%) to 2.6% (95% CI: 2.0%–3.6%). Comparing breast cancer mortality rates for 2014–2018 in the Toledo Health Area with the rest of Castilla-La Mancha, which had similar cancer treatment access and management protocols but without digital breast tomosynthesis, the crude mortality rate was 17.79 (95% CI: 15.38 -20.19) vs. 24.76 per 100,000 (95% CI: 26.12–23.39), respectively. The cumulative risk of death was also significantly lower for the Toledo Health Area than for Castilla-La Mancha. Conclusion The introduction of digital breast tomosynthesis improved screening quality indicators. Breast cancer mortality simultaneously decreased with respect to the rest of Castilla-La Mancha. Further research is needed to assess the long-term results, and the role that the redesign may have played in reducing mortality.

A prognostic nomogram for predicting breast cancer survival based on mammography and AJCC staging

“…An observational study reported a significant increase in breast cancer detection rates, from 4.0 to 5.4 per 1000 screenings, following the introduction of breast tomosynthesis into clinical screening practice [ 21 ]. Previous research has also demonstrated the long-term benefits of DBT screening compared to DM [ 11 ]. In the present study, the purpose and modality of mammography emerged as important predictors for determining long-term outcomes, highlighting the importance of effective breast cancer screening methods in improving patient prognosis.…”

“…Additionally, very low mammographic breast density has been identified as an independent prognostic feature associated with higher tumor grade and worse survival in newly diagnosed breast cancer patients [ 10 ]. Castellano et al reported a decrease in breast cancer mortality in areas where digital breast tomosynthesis (DBT) screening was implemented compared to conventional digital mammography (DM) [ 11 ].…”

Dielectric Characterization of Breast Biopsied Tissues as Pre-Pathological Aid in Early Cancer Detection: A Blinded Feasibility Study

“…Diagnosed in 2.3 million women and accounting for 685,000 deaths worldwide in 2020, breast cancer is the most common cancer in women worldwide and represents the leading cause of death [ 1 ]. Breast cancer management involves a comprehensive approach to diagnosing and treating this prevalent disease, in which early detection is crucial to reduce mortality and typically achieved through regular screening [ 2 , 3 , 4 , 5 ].…”

A multicentric, single arm, prospective, stratified clinical investigation to evaluate MammoWave’s ability in breast lesions detection

“…Current screening programs for early breast cancer (BC) detection have been a topic of worldwide discussion due to some drawbacks of the current gold standard technique, mammography [1][2][3]. It is widely known that mammography, and its latest developments (Digital Breast Tomosynthesis, DBT [4]), limits its use in population-based screening programs to both a very specific age range (usually 50 to 69 years old women), and a limited screening frequency, usually biennial [2]. Meanwhile, newer studies estimate that BC is diagnosed in 6.6% of women younger than 40 [5], and more than 20% of BC cases in Europe occur in women when they are below the age of 50 [6].…”